Clinical trial · Observational
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma: Observational Study
NCT04416646CI-TRIAL-00107858ZEBRAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cabozantinib | Drug | Cabozantinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clinical tolerability of Cabozantinib
- timeFrame
- Average of 1 year
- description
- the main purpose is to register the Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]
Secondary outcomes (1)
- measure
- Description of response rate of patients treated with Cabozantinib.
- timeFrame
- From date of randomization until the date of last documented, assessed up to 18 months"
- description
- according to RECIST criteria, only patients with measurable disease will be evaluated for response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age 70 years * Histological diagnosis of Renal Cell Carcinoma (any histology, with the exclusion of urothelial carcinomas) * Locally advanced disease or metastatic disease (any site, measurable or non- measurable lesions), progressing after at least one line of VEGFR-targeted therapy (as per official registration of the drug at AIFA, in case of extension to first-line treatment, TKI-naïve patients will also be eligible), with or without previous exposure to check-point inhibitors. * Life expectancy of at least 3 months * Adequate hepatic, renal and bone marrow function as judged by the treating oncologist. * Written informed consent Exclusion Criteria: * Inability to swallow cabozantinib tablets * Serious comorbidities or cognitive impairment, which may interfere with cabozantinib administration and/or patient's follow up, as judged by the treating physician * Absence of a reliable caregiver, as judged by the treating physician
References
Publications (0)
Data not yet available
No reference posted for this study.